* Agency expects to ask advisory panel for input this year
* Drugs include Amgen’s Aranesp, J&J’s Procrit
WASHINGTON, Jan 6 (Reuters) - U.S. regulators plan to ask outside experts to re-evaluate the use of Amgen Inc (AMGN.O) and Johnson & Johnson (JNJ.N) anemia drugs when given to patients with chronic kidney disease.
Food and Drug Administration officials, in an article published in the New England Journal of Medicine on Wednesday, said the agency “anticipates convening a public advisory committee meeting in 2010 to reevaluate the use of” drugs known as erythropoiesis-stimulating agents (ESAs) in people with chronic kidney disease.
ESAs include Amgen’s Aranesp and Epogen and J&J’s Procrit.
The drugs came under scrutiny in recent years after studies showed high doses could lead to heart complications or death. Strong warnings were added and sales slumped, but the medicines remain widely used. (Reporting by Lisa Richwine; editing by Andre Grenon)